Related Experiment Video

Updated: Jun 11, 2025

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.3K

The implications of measuring lipoprotein(a) in clinical practice

Mahmoud Barbir1, Alison Pottle1, Stefan R Bornstein2,3

  • 1Harefield Hospital, part of Guy's and St Thomas' NHS Foundation Trust, UK.

Global Cardiology Science & Practice
|October 1, 2024
PubMed

Insights

Lipoprotein(a) (Lp(a)) is a key risk factor for cardiovascular diseases like atherosclerotic cardiovascular disease and aortic valve stenosis. Current screening and management face challenges, with clinical practice recommendations pending ongoing trial results.

Area of Science:

  • Cardiology
  • Biochemistry
  • Genetics

Background:

  • Lipoprotein(a) (Lp(a)) is identified as a significant, independent causal risk factor for atherosclerotic cardiovascular disease (ASCVD).
  • Lp(a) also plays a critical role in the pathogenesis of calcific aortic valve stenosis.
  • Elevated Lp(a) levels are associated with increased cardiovascular risk.

Discussion:

  • Challenges persist in the effective screening and management of individuals with elevated Lp(a) levels.
  • Current primary and secondary prevention strategies for Lp(a)]-associated ASCVD require refinement.
  • Understanding the clinical utility of Lp(a) in diverse patient populations is crucial.

Key Insights:

  • Lp(a) is a validated genetic determinant of ASCVD and calcific aortic valve stenosis.
  • The clinical implementation of Lp(a) testing and targeted therapies is still evolving.
  • Further research is needed to optimize Lp(a) risk stratification and intervention.

Outlook:

  • Future clinical practice guidelines for Lp(a) management are anticipated.
  • Ongoing clinical trials are expected to provide critical data for future recommendations.
  • The development of novel therapeutic strategies targeting Lp(a) is a key area of research.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.0K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Related Concept Videos

Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
135
Coronary Artery Disease IV: Medical Management01:26

Coronary Artery Disease IV: Medical Management

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
11
Atherosclerosis II: Clinical manifestations and prevention01:27

Atherosclerosis II: Clinical manifestations and prevention

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
2
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
519
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
63
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2